Registry Data Instead Of Randomized Control May Accelerate HF Device Trials
This article was originally published in The Gray Sheet
Executive Summary
Large heart failure registries will provide data that could be used in lieu of a randomized control in trials of new heart failure devices, according to participants at the annual Transcathether Cardiovascular Therapeutics HHS "Town Hall Meeting" Oct. 19
You may also be interested in...
Thoratec Projects Market Growth As CMS Revamps VAD Coverage Criteria
Thoratec anticipates that the market for HeartMate will expand if CMS revises its standards for facilities that implant ventricular assist devices (VAD) as a destination therapy, a company official said
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.